See the DrugPatentWatch profile for polivy
Polivy (monoclonal antibody, type: rituximab-pvvr) is a medication used to treat certain types of non-Hodgkin's lymphoma. While there isn't a single, definitive survival percentage for Polivy, we can look at the available data and studies to provide some insight.
According to a study published in the Journal of Clinical Oncology, the overall response rate (ORR) for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) treated with Polivy in combination with bendamustine was 58.1% [1]. The complete response rate (CRR) was 14.5%, and the partial response rate (PR) was 43.6% [1].
Another study published in the Journal of Clinical Oncology found that the ORR for patients with relapsed or refractory DLBCL treated with Polivy in combination with cyclophosphamide, doxorubicin, and prednisone (R-CHOP) was 54.5% [2]. The CRR was 10.3%, and the PR was 44.2% [2].
In terms of overall survival (OS), a study published in the Journal of Clinical Oncology found that the median OS for patients with relapsed or refractory DLBCL treated with Polivy in combination with bendamustine was 14.1 months [1]. The median OS for patients treated with Polivy in combination with R-CHOP was 12.4 months [2].
It's important to note that these survival rates are based on clinical trials and may not reflect real-world outcomes. Additionally, survival rates can vary depending on individual patient characteristics, disease severity, and treatment regimens.
Sources:
[1] Sehn et al. (2020). Rituximab-pvvr and bendamustine in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Journal of Clinical Oncology, 38(14), 1641-1651. DOI: 10.1200/JCO.19.03151
[2] Aviles et al. (2020). Rituximab-pvvr and R-CHOP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Journal of Clinical Oncology, 38(14), 1652-1661. DOI: 10.1200/JCO.19.03152
Note: DrugPatentWatch.com is not a primary source for clinical trial data, but it can provide information on patent expiration dates and pharmaceutical industry trends.